

**Astellas, U.S. Independent Medical Education
Call for Independent Medical Education Grant Applications
Menopause- Vasomotor Symptoms
Release Date: January 5, 2026**

I. Background

Astellas (the “Company”) is committed to supporting high quality, evidence-based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and management. The intent of this Call for Grant Applications (CGA) is to encourage organizations to submit grant applications for independent CME/CE certified education designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence and performance of healthcare professionals, and advance patient health outcomes. “Independent” means that the projects funded by the company are the full responsibility of the recipient organization. The Company does not have influence over any aspect of the supported projects and only asks for interim and final outcomes reports including a description of the impact of the projects.

When responding to this CGA, please adhere to the following principles in addition to the established guidelines for the Astellas IME grant application process. All applications must be submitted online through the Astellas Grant Management System, accessible at www.astellasgrants.com.

II. Eligibility

Geographic Scope:	United States Only
Applicant Eligibility Criteria:	<p>Eligible applicants (the “Organization”) include hospitals, academic medical centers and medical schools (Note: the CME Office must submit the request for accredited activities); national-level professional medical associations/societies; medical education companies; and publishers of medical and scientific publications.</p> <p>Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations are strongly encouraged. Please note all partners must have a relevant role and the requesting Organization must have a key role in the project. For programs offering continuing education credit, the requesting Organization must be the accredited grantee.</p>

III. Requirements

Date CGA Issued:	January 5, 2026
Application Deadline:	<p>Executive summaries will be accepted on an ongoing basis until January 23, 2026.</p> <p>Eligible applicants will be notified no later than January 26, 2026.</p> <p>Full proposals are due no later than February 13, 2026. Review is prioritized based on date of receipt, program requirements, and available budget.</p>
Anticipated Grant Decision Date:	No later than February 27, 2026
Educational Area:	Menopause- Vasomotor Symptoms
Target Audiences:	OB/GYNs and other members of the interprofessional and multidisciplinary team involved in the management of women's health conditions relevant to the identified educational gaps
Specific Education Gaps to Be Addressed:	<p>The purpose of this CGA is to encourage Organizations to submit grant applications for independent CME/CE education delivered in conjunction with both the ACOOG Annual Clinical Assembly and the ACOG Annual Clinical & Scientific Meeting. The objective of this CGA is to improve the management of Menopause- Vasomotor Symptoms by supporting the understanding of the increasingly complex patient journey and close knowledge gaps. Practice gaps in Menopause- Vasomotor Symptoms which have been identified in the public healthcare landscape include:</p> <ul style="list-style-type: none">• Epidemiology, burden, and impact of VMS due to menopause• Issues and challenges with current VMS treatment options• Importance of shared decision making and an individualized approach to the assessment and management of VMS due to menopause• Effective patient communication related to treatment options, risk assessment, and shared decision making• Increase patient understanding of their role in shared decision-making and patient knowledge of current therapeutic options <p>Proposals must address at least two of the gaps identified above.</p> <p>Activities focused on therapies or treatment will not be considered.</p>
How to Submit:	<p>Please go to www.astellasgrants.com and sign in. First-time users should click "REGISTER NOW".</p> <p>Select the following Area of Interest: Menopause- Vasomotor Symptoms</p> <p>Requirements for submission:</p>

	<p>You must include “2026-CGA-01” in the “Activity Title” of your program’s online submission prior to the title.</p> <p>Complete all required sections of the online application and upload the Completed proposal.</p> <p>If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page.</p> <p>IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed.</p>
Expected Approximate Monetary Range of Grant Applications:	<p>Individual requests up to \$250,000 will be considered for funding. The amount of any grant funded by the Company for any project may vary from the amount requested.</p> <p>Multi-supported initiatives are highly preferred. If multi-support isn’t possible, the following must be included:</p> <ul style="list-style-type: none"> • Indicate how many companies were sought for monetary funding support, and their responses. • How will you ensure that the activity is evidence-based, gives a balanced view of therapeutic options, and is free from commercial bias <p>Collaborations among multiple Organizations are encouraged.</p>

IV. **Process**

1. All providers are required to submit an **Executive Summary of the Proposal** through CyberGrants and complete all mandatory fields in the system. At this stage, a **high-level budget attachment** must also be included.
2. An **Executive Summary document** (maximum 5 pages) should also be uploaded. This serves as an introductory overview of the proposed initiative and should include:
 - **Practice gaps, underlying educational needs, and root causes** identified among the provider’s learners
 - Draft Agenda
 - **Intended audience(s)**
 - Describe any **collaborations**
 - **Projected participation:** number of learners and completers for each modality, broken down by specialty (e.g., live and on-demand enduring)
 - **Learning objectives**
 - **Educational design and instructional modalities** to be employed
 - **Expected level of outcomes** (Moore’s framework)
 - **Timeline:** content development start date, activity start and end dates, and launch date(s) for each modality
 - **Budget overview**
 - Requested funding amount
 - Total project budget

Summaries will be reviewed and eligible applicants will be invited to submit a full proposal, based on **the requirements outlined in Astellas' Proposal Guidelines**. Full proposals should be no longer than 15 pages in length, and should only include information that is relevant to the proposed activity. **Only one proposal per provider per CGA. Multiple proposals from a provider for a single CGA will not be considered.**

V. **Terms and Conditions**

1. This CGA does not commit the Companies or their partners to award a grant or a grant of any particular amount if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.
2. The Companies reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety at any time for any reason.
3. All communications about the CGA must be sent to Astellas IME at grants@astellas.com <http://www.astellasgrants.com/>. Applicants should not contact other departments within Astellas regarding this CGA. Failure to comply may affect the acceptance of your application.
4. The decision by the Companies to provide a grant will not be determined in a manner that takes into account the volume or value of any business otherwise generated between Astellas and any applicant.
5. Applicant shall have complete control over the content, development and implementation of the education programs and/or materials, including, if applicable, the selection of faculty. Any information provided as part of the program regarding any products, including, without limitation, Astellas and/or Pfizer products, shall be objective and based on scientific methods generally accepted in the medical community.

6. US Transparency Reporting

A. To enable Astellas to comply with its legal obligations, in the event that any payment or other transfer of value (hereinafter "payment" or "payments") is provided, either directly or indirectly, to a covered recipient (as defined below) or to another individual or entity at the request or on behalf of a covered recipient, in connection with an approved grant request, Organization shall implement procedures to track the payments and shall report the payments to Astellas upon grant reconciliation and in accordance with any written instructions that Astellas may provide to Organization. Required reporting information includes, but shall not be limited to:

- a. Name and primary business address of covered recipient
- b. For physician covered recipient, NPI, state professional license number and specialty.
- c. Amount of payment
- d. Date of payment
- e. Form of payment
- f. Nature of payment

B. In addition to these tracking and reporting obligations, Organization shall inform such covered recipient at the time of payment that his/her/its acceptance of such payment may be disclosed in

a report filed with government authorities by Astellas as required by law and that government authorities may make the reported information publicly available.

C. For purposes of this Agreement, the term “covered recipient” has the meaning ascribed to it in 42 C.F.R. § 403.902 and any similar state law which requires tracking and reporting of payments to a government agency for payment transparency purposes.

Frequently Asked Questions related to Astellas’ Sunshine Act Reporting Requirements are available on the website www.astellasgrants.com.